Recent alternative approaches of vascular drug-eluting stents

被引：4
作者：
Han C.-M. [1 ]
Park K.-S. [1 ]
Joung Y.K. [1 ,2 ]
机构：
[1] Center for Biomaterials, Korea Institute of Science and Technology, Seoul
[2] Division of Bio-Medical Science and Technology, University of Science and Technology (UST), Daejeon
来源：
Journal of Pharmaceutical Investigation | 2018年 / 48卷 / 2期
关键词：
Anti-inflammation; Drug eluting stent; Re-endothelialization; Restenosis; Thrombosis; Vascular stent;
D O I：
10.1007/s40005-017-0378-9
中图分类号：
学科分类号：
摘要：
Vascular stent is tubular shaped medical device designed to treat occluded circulatory or digestive systems by opening the blocked vascular sites. Originally stents were made of bare metals, such as stainless steel and cobalt–chromium alloys, due to their inherent corrosion resistance and good mechanical properties. Damage of intimal layer during expansion of stent, however, have caused neointimal hyperplasia resulting in in-stent restenosis which is one of main complications of vascular stent treatment. Drug-eluting stents (DESs) were introduced to alleviate this restenosis by local delivery of anti-proliferative drugs to the implanted or inserted site. The DES systems have been developed over the years by making changes in its main component, namely, drug, polymeric coating layer and expandable scaffold. Nevertheless, late thrombosis caused by drugs themselves and polymeric coating layer still remains as a serious problem of DES systems. Numerous studies, therefore, consistently focus on more advanced DES systems to solve the current issues. In this mini review article, we cast an opinion on how to improve the potential of DES system by means of (i) summarizing the history of DES system developed so far and (ii) updating current advances for the future generation of DES system. © 2017, The Korean Society of Pharmaceutical Sciences and Technology.
引用
收藏
页码：153 / 165
页数：12
相关论文
共 105 条
[21]  
Choi D.H., Kang S.N., Kim S.M., Gobaa S., Park B.J., Kim I.H., Joung Y.K., Et al., Growth factors-loaded stents modified with hyaluronic acid and heparin for induction of rapid and tight re-endothelialization, Coll Surf B Biointerfaces, 141, pp. 602-610, (2016)
[22]  
Clowes A.W., Karnowsky M.J., Suppression by heparin of smooth muscle cell proliferation in injured arteries, Nature, 265, pp. 625-626, (1977)
[23]  
Collet C., Sotomi Y., Cavalcante R., Suwannasom P., Tenekecioglu E., Onuma Y., Serruys P.W., Coronary stent thrombosis: what have we learned?, J Thorac Dis, 8, pp. 1398-1405, (2016)
[24]  
Cui S., Liu J.H., Song X.T., Ma G.L., Du B.J., Lv S.Z., Meng L.J., Et al., A novel stent coated with antibodies to endoglin inhibits neointimal formation of porcine coronary arteries, BioMed Res Int, 2014, (2014)
[25]  
Dong C., Song D., Cairney J., Maddan O.L., He G., Deng Y., Antibacterial study of Mg(OH)<sub>2</sub> nanoplatelets, Mater Res Bull, 46, pp. 576-582, (2011)
[26]  
Dunne M., Corrigan O.I., Ramtoola Z., Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles, Biomaterials, 21, pp. 1659-1668, (2000)
[27]  
Ellis S.G., Kereiakes D.J., Metzger D.C., Caputo R.P., Rizik D.G., Teirstein P.S., Litt M.R., Et al., Everolimus-eluting bioresorbable scaffolds for coronary artery disease, N Engl J Med, 373, pp. 1905-1915, (2015)
[28]  
Elnaggar M.A., Seo S.H., Gobaa S., Lim K.S., Bae I.-H., Jeong M.H., Han D.K., Et al., Nitric oxide releasing coronary stent: a new approach using layer-by-layer coating and liposomal encapsulation, Small, 12, pp. 6012-6023, (2016)
[29]  
Ernst A., Bulum J., New generations of drug-eluting stents-A brief review, EMJ Int Cardiol, 1, pp. 100-106, (2014)
[30]  
Finn A.V., Kolodgie F.D., Harnek J., Guerrero L.J., Acampado E., Tefera K., Skorija K., Et al., Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents, Circulation, 112, pp. 270-278, (2005)
12345678910